| Objective To investigate the correlation between the expression of serum pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PlGF) and gestational metabolic syndrome(GMS). Methods A total of 121 GMS patients from March 2018 to December 2019 in Zaozhuang Mining Group Central Hospital were selected as observation group, and 121 normal pregnant women without complications were selected as control group. The clinical data of the two groups were collected, serum PAPP-A, PlGF expression levels were collected, and the changes of each index were analyzed. Results The serum PAPP-A level of the observation group was (144.69±38.95)mg/L, PlGF was (83.53±22.83)pg/mL, which were lower than those in the control group (P<0.05); the expression levels of PAPP-A and PlGF in the observation group were negatively correlated with systolic blood pressure, triglyceride(TG), total cholesterol, low-density lipoprotein cholesterol(LDL-C) and fasting blood glucose(P<0.05), and positively correlated with high-density lipoprotein cholesterol(P<0.05); the sensitivity (81.00%) and specificity (83.50%) of serum PAPP-A and PlGF in the diagnosis of GMS were higher than that of the two alone; body mass index ≥ 25 kg/m2, hypertension, TG ≥ 3.23 mmol/L, high expression of LDL-C, GDM, low expression of PAPP-A and low expression of PlGF were independent risk factors of GMS in pregnant women(P<0.05). The incidence of macrosomia and preterm infants in PAPP-A low expression group was 19.67% and 34.43% respectively, which was higher than that in PAPP-A high expression group (3.33% and 13.33%,P<0.05);the incidence of macrosomia and preterm infants in patients with low expression of PlGF was 17.46% and 34.92% respectively, which was higher than that in patients with high expression of PlGF(5.17% and 12.07%,P<0.05). Conclusions The low expression of PAPP-A and PlGF in GMS patients can be used for early diagnosis and pregnancy outcome evaluation of GMS. |
